409 General Discussion Figure 2.2. Continued. 1STOPP C5 comprised 1.7% (n = 60/3465) of all generated STOPP signals in all OPERAM trial sites (Switzerland, Belgium, Ireland and the Netherlands). 2Percentage of accepted signals by the pharmacotherapy team with the number of generated STOPP C5 signals (n = 60) as the denominator in all OPERAM trial sites. 3No data on agreement after discussion with patient and physician was available for recommendations related to STOPP C5. 4The implementation of STOPP/START-based recommendations was calculated at two months after discharge with the number of recommendations based on STOPP C5 as the denominator. 5Based on results from Schaefer et al (2021) [61]. Patients taking DOAC and ASA (without indication) experienced more bleeding events compared with DOAC monotherapy (26.0 bleeds vs 31.6 bleeds per 100 patient years, P = 0.01). This equals a NNH of 24 patients (i.e. unindicated aspirin needs to be discontinued in 24 DOAC users to prevent one bleeding). DOAC = direct oral antigoaculant; ASA = acetylsalicylic acid; PPI = proton pump inhibitor; DRA = drug related hospital admission; NNH = number needed to harm. 5
RkJQdWJsaXNoZXIy MTk4NDMw